Le Lézard
Classified in: Health
Subjects: BFA, CPN, AVO

Rishi Kumar Determined To Oppose Big Money In Politics


SARATOGA, Calif., Jan. 29, 2020 /PRNewswire/ -- Democratic candidate for U.S Congress CA-18 Rishi Kumar* issued this statement ahead of the California Primary:

"I am running for Congress to represent the people's interests, not special interests. I believe in making fearless people-centric choices to address pressing community challenges. As your congressman, I will never accept PAC money or special interest group money."

Former Saratoga mayor Stan Bogosian endorses Rishi Kumar. "Rishi gets things done. While serving on the Saratoga City Council, Rishi successfully led the effort to stop repeated attempts by the San Jose Water Company to impose predatory rate increases. He will apply the same tenacity to rein in the outrageous price increases of Big Pharma. Unlike his opponent Anna Eshoo, Rishi does NOT accept contributions from Big Pharma or any other Special Interest Groups."

Here's what people have said about Anna Eshoo:
"Rep. Anna Eshoo, House Health Subcommittee Chair, has taken more pharmaceutical money than any other representative. She has sponsored legislation backed by the pharmaceutical interests funding her campaigns...(Eshoo has given) pharmaceutical companies 12-year exclusivity periods for biologic drugs, beyond the length of their patents, to protect them from competition by the generic drug industry."-- Donald Shaw, Money-in-politics reporter, co-founder of Sludge Magazine 

"Does it make sense (for Eshoo) to support a bill that sustains high drug prices, stifles innovation, and reduces our patients' access to life saving drugs?"-- The Mercury News (op-ed) 

"A scathing report by the Federal Trade Commission warned that the Eshoo legislation would ensure sky-high drug prices and stifle innovation on the most promising frontier of medical research."-- The San Francisco Chronicle

"Anna Eshoo's record on drug prices is terrible, and the reason why is obvious. She's taken enormous sums of money from drug corporations, and she does their bidding in Washington. Eshoo's name has for years been conspicuously absent from important pieces of legislation that could lower drug prices."-- David Mitchell, founder of Patients For Affordable Drugs Action 

Rishi Kumar will never accept PAC money or Special Interest Group money.
*Rishi Kumar, a progressive capitalist, is running for U.S Congress from Silicon Valley CA-18, challenging Rep. Anna Eshoo in the March 3rd, 2020 open top-2 primary election. Rishi is a hi-tech executive, councilmember of Saratoga, CA, and executive board member of the California Democratic Party (AD28).

 

Campaign slogan - "Your interests, Not Special Interests." As an IBM engineer, Rishi found his calling as an activist stepping up for complex people challenges that he couldn't ignore. Rishi is not a career politician and brings a fearless data-driven agenda to deliver results

SOURCE Rishi Kumar for Congress 2020


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: